A A A
-->

Publikationen

Publikationen der Jahre: 2012   2011   2010   2009    2008   2013   2014   2015

2015

Höglinger GU, Alvarez-Fischer D, Arias-Carrión O, Djufri M, Windolph A, Keber U, Borta A, Ries V, Schwarting RK, Scheller D, Oertel WH. A new dopaminergic nigro-olfactory projection. Acta Neuropathol 2015;130(3):333-48.

Keber U, Klietz M, Carlsson T, Oertel WH, Weihe E, Schäfer MK, Höglinger GU, Depboylu C. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Neuroscience 2015;298:302-17.

Chiu WH, Depboylu C, Hermanns G, Maurer L, Windolph A, Oertel WH, Ries V, Höglinger GU. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. Neuropharmacology 2015;95:367-76.

Depboylu C, Rösler TW, de Andrade A, Oertel WH, Höglinger GU. Systemicallyadministered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease. J Neurochem 2015;133(4):590-7.

2014

Depboylu C, Klietz M, Maurer L, Oertel WH, Kobayashi K, Weihe E, Höglinger GU, Schäfer MK. Transcriptional and structural plasticity of tyrosine hydroxylase expressing neurons in both striatum and nucleus accumbens following dopaminergic denervation. J Chem Neuroanat 2014;61-62:169-75.

Rösler TW, Matusch A, Librizzi D, Arias-Carrión O, Freundlieb N, Hoeffken H, Oertel WH, Depboylu C, Höglinger GU. Diesterified derivatives of 5-iodo-2'-deoxyuridine as cerebral tumor tracers. PLoS One 2014;9(7):e102397.

Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D, Starmann J, Macas J, Karpova D, Devraj K, Depboylu C, Landfried B, Arnold B, Plate KH,Höglinger G, Sültmann H, Altevogt P, Momma S. Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation. PLoS Biol 2014;12(6):e1001874.

Lahut S, Vadasz D, Depboylu C, Ries V, Krenzer M, Stiasny-Kolster K, Basak AN, Oertel WH, Auburger G. The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome. Neurogenetics 2014;15(3):189-92.

Depboylu C. Non-serine-phosphorylated tyrosine hydroxylase expressing neurons are present in mouse striatum, accumbens and cortex that increase in number following dopaminergic denervation. J Chem Neuroanat 2014;56:35-44.

Oertel WH, Depboylu C, Krenzer M, Vadasz D, Ries V, Sixel-Döring F, Mayer G. [REM sleep behavior disorder as a prodromal stage of α-synucleinopathies: symptoms, epidemiology, pathophysiology, diagnosis and therapy]. Nervenarzt 2014;85(1):19-25.

Chiu WH, Carlsson T, Depboylu C, Höglinger GU, Oertel WH, Ries V. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. Neuropharmacology 2014;79:212-21.

2013

 

Chiu WH, Carlsson T, Depboylu C, Höglinger GU, Oertel WH, Ries V.  Selegiline normalizes, while l-DOPA sustains the increased number ofdopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease. Neuropharmacology 2013;79C:212-21.

Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC,Hunot S, Hartmann A. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 2013;3:1393.

Depboylu C, Maurer L, Matusch A, Hermanns G, Windolph A, Béhé M, Oertel WH, Höglinger GU. Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry. Neuroimage 2013;79:191-200.

Li G, Nowak M, Bauer S, Schlegel K, Stei S, Allenhöfer L, Waschbisch A, Tackenberg B, Höllerhage M, Höglinger GU, Wegner S, Wang X, Oertel WH, Rosenow F, Hamer HM. Levetiracetam but not valproate inhibits function of CD8+ T lymphocytes. Seizure 2013;22(6):462-6.

Respondek G, Roeber S, Kretzschmar H, Troakes C, Al-Sarraj S, Gelpi E, Gaig C, Chiu WZ, van Swieten JC, Oertel WH, Höglinger GU. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013;28(4):504-9.

 

2012

 

Depboylu C, Weihe E, Eiden LE. Lentiviral infection of rhesus macaques causes long-term injury to cortical and hippocampal projections of prostaglandin-expressing cholinergic basal forebrain neurons. J Neuropathol Exp Neurol 2012;71(1):15-27.

Matusch A, Fenn LS, Depboylu C, Klietz M, Strohmer S, McLean JA, Becker JS. Combined elemental and biomolecular mass spectrometry imaging for probing the inventory of tissue at a micrometer scale. Anal Chem. 2012 Apr 3;84(7):3170-8.

Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Höglinger GU. Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol. 2012 Dec;238(2):183-91.

Depboylu C, Höllerhage M, Schnurrbusch S, Brundin P, Oertel WH, Schrattenholz A, Höglinger GU. Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease. Neurosci Lett 2012;531(2):209-14.

 

 
2011

 

Depboylu C, Weihe E, Eiden LE. COX1 and COX2 expression in non-neuronal cellular compartments of the rhesus macaque brain during lentiviral infection. Neurobiol Dis 2011;42(1):108-15.

Depboylu C, Schäfer MK, Arias-Carrión O, Oertel WH, Weihe E, Höglinger GU. Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J Neuropathol Exp Neurol 2011;70(2):125-32.

Carlsson T, Schindler FR, Höllerhage M, Depboylu C, Arias-Carrión O, Schnurrbusch S, Rösler TW, Wozny W, Schwall GP, Groebe K, Oertel WH, Brundin P, Schrattenholz A, Höglinger GU. Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 2011;117(6):1066-74.

Depboylu C, Schorlemmer K, Klietz M, Oertel WH, Weihe E, Höglinger GU, Schäfer MK. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease. J Neuroimmunol 2011;236(1-2):39-46.

Rösler TW, Depboylu C, Arias-Carrión O, Wozny W, Carlsson T, Höllerhage M, Oertel WH, Schrattenholz A, Höglinger GU. Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1. Neuropharmacology 2011;61(8):1413-8.

Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R. Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis 2011;8(6):438-46.

Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011;43(7):699-705.

Ries V, Oertel WH, Höglinger GU. Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy. J Mol Neurosci 2011;45(3):684-9.

Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE. Cost-of-illness in multiple system atrophy and progressive supranuclear palsy. J Neurol 2011;258(10):1827-34.

Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Höglinger G, Hamon M, Tronche F, Hirsch EC, Vyas S. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A 2011;108(16):6632-7.

Stamelou M, Christ H, Reuss A, Oertel W, Höglinger G. Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Mov Disord 2011;26(5):901-5.

Stamelou M, Knake S, Oertel WH, Höglinger GU. Magnetic resonance imaging in progressive supranuclear palsy. J Neurol 2011;258(4):549-58.

 

2010

Bach JP, Kumar N, Depboylu C, Noelker C, Klockgether T, Bacher M, Balzer-Geldsetzer M, Dodel R (2010) Copper deficiency associated with severe neurological disorder – A genetic work-up of possible mutations in copper transport proteins. J Neurol Sci 291(1-2):95-7.

Bach JP, Oertel WH. Kognitive Defizite (Demenzen) als Komorbiditäten neurologischer Erkrankungen.

Bach JP, Riedel O, Pieper L, Klotsche J, Dodel R, Wittchen HU (2010) Health-Related Quality of Life in Patients with a History of Myocardial Infarction and Stroke. Cerebrovasc Dis 31(1):68-76.

Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, Popp J, Noelker C, Reese JP, Al-Abed Y, Dodel R (2010) The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med. 16(3-4):116-21.

Balakrishnan K, Andrei-Selmer LC, Selmer T, Bacher M, Dodel R (2010) Comparison of Intravenous Immunoglobulins for Naturally Occurring Antibodies against b-Amyloid. J Alzheimer’s disease 20(1):135-43.

Bauer S, David Rudd G, Mylius V, Hamer HM, Rosenow F. Lacosamide intoxication in attempted suicide. Epilepsy Behav. 2010;17:549-51.

Bauer S, Rudd G., Mylius V, Hamer, HM, Rosenow F. Lacosamide intoxication in attempted suicide - A case report Epi & Behavior 2010:17:549–551.

Bodden M, Kalbe E, Dodel R (2010) Demenz bei der Parkinsonerkrankung. DNP 5: 45-49

Bodden ME, Mollenhauer B, Trenkwalder C, Cabanel N, Eggert K, Unger M, Oertel WH, Kessler J, Dodel R, Kalbe E (2010) Affective and cognitive Theory of mind in Patients with Parkinson’s Disease. Parkinsonism Relat Disorders 16(7):466-470.

Buob A, Winter H, Kindermann M, Becker G, Moeller JC, Oertel WH, Boehm M. Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson’s disease. Clin Res Cardiol 2010; 99(11): 701-706

de Kovel CGF, Trucks H, HelbigI, Leu C, Kluck C, Muhle H, von Spiczak S, Obermeier T, Franke A, Itsara A, Mefford HC, Baker C, Cooper G, Kleefuß-Lie AA, Hallmann K, Steffens M, Gaus V, Schmitz B, Klein KM, Hamer HM, Rosenow F, Brilstra EH, Kasteleijn-Nolst Trenité D, Swinkels MEM, Weber YG, Unterberger I, Zimprich F, Urak L, Fuchs K, Feucht M, Møller RS, Hjalgrim H, Rückert IM, Wichmann HE, Nürnberg P, Elger CE, Lerche H, Stephani U, Schreiber S, Koeleman BPC, Lindhout D, Eichler EE, Sander T. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalised epilepsy. Brain 2010;133:23-32.

Decher N, Streit A, Rapedius M, Netter M, Marzian S, Ehling P, Schlichthörl G, Craan T, Renigunta V, Köhler A, Dodel R, Navarro-Pollanco R, Preisig-Müller R, Klebe G, Budde T, Baukrowitz T, Daut J (2010) RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels. EMBO J 29(13):2101-13.

Depboylu C, Schäfer MKH, Arias-Carrión O, Oertel WH, Weihe E, Höglinger GU. Possible Involvement of Complement Factor C1q in the Clearance of Extracellular Neuromelanin from the Substantia Nigra in Parkinson’s Disease. J Neuropath Exp Neurology. In press

Dodel I, Müller N, Münchau A, Reese JP, Balzer-Geldsetzer M, Dodel R, Oertel WH, Müller-Vahl K (2010) Healthcare utilization in patients with Gilles de la Tourette's syndrome. Mov Disord (ahead of print)

Dodel I, Reese JP, Müller N, Münchau A, Balzer-Geldsetzer M, Wasem J, Oertel WH, Dodel R, Müller-Vahl K (2010) Cost of illness in patients with Gilles de la Tourette's syndrome. J Neurol. 2010 Jul;257(7):1055-61.

Dodel R (2010) Kognitive Störungen bei neurologischen Erkrankungen. Nervenheilkunde 29(11):709.

Dodel R, Happe S, Peglau I, Mayer G, Wasem J, Reese JP, Giani G, Geraedts M, Trenkwalder C, Oertel WH, Stiasny-Kolster K (2010) Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting. Pharmacoeconomics 28(5):381-93.

Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70(5):513-28.

Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks D, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [11C]-(R)-PK11195 PET (MEMSA-Trial). Mov Disord 2010; 25(1): 95-107

Dodel R, Winter Y, Ringel F, Spottke A, Gharevi N, Müller I, Klockgether T, Schramm J, Urbach H, Meyer B (2010) Cost-of-Illness in Subarachnoid Hemorrhage. Stroke (ahead of print)

Dodel RC, Klockgether T (2010) Kurzlehrbuch der Neurologie für Studenten. Wissenschaftliche Verlagsgesellschaft, Stuttgart.

Eggert K, Oertel WH. Die Parkinson-Krankheit: Therapie der motorischen Störungen. In: Oertel WH, Deuschl D, Poewe W (Hrsg). Neurologische Bewegungsstörungen. Thieme Verlag 2010 in Bearbeitung

Eggert K, Skogar Ö, Amar K, Luotonen L, Kuoppamäki M, Leinonen M, Nissinen H, Oertel WH, on behalf of the SENSE study group. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with early wearing-off: efficacy, safety and feasibility – an open-label, 6-week study. J Neural Transm 2010; 117: 333-342

Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofri M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W; German Competence Network on Parkinson’s disease. Safety and efficacy of perampanel in advanced Parkinson’s disease: a randomized, placebo controlled study. Mov Disord 2010; 25(7): 896-905

Ernst A, Buerger K, Hartmann O, Dodel R, Noelker C, Sommer N, Schwarz M, Koehrle J, Bergmann A, Hampel H (2010) Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation. J Neuroimmunol. 221(1-2):62-7.

Haag A, Barth S, Zibelius M, Hermsen A, Menzler K, Oertel WH, Hamer HM, Rosenow F, Knake S. Memory for public events in patients with unilateral temporal lobe epilepsy. Epilepsy Behav. 2010;17:246-51.

Haag A, Moeller N, Knake S, Hermsen A, Oertel WH, Rosenow F, Hamer HM. Language lateralization in children using functional transcranial Doppler sonography. Dev Med Child Neurol 2010; 52(4): 331-336

Haag A, Strzelczyk A, Bauer S, Kühne S, Hamer HM, Rosenow R. Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of “newer” versus “classic” drugs: Results of the “Compliant 2006” survey in 907 patients. Epilepsy&Behav 2010;19:618-622.

Hagemann S, Faude A, Rabenstein M, Balzer-Geldsetzer M, Nölker C, Bacher M, Dodel R (2010) Reducing sample complexity of polyclonal human autoantibodies by chromatofocusing. J Chromatogr B Analyt Technol Biomed Life Sci 878:2249-2254.

Hamer HM, Rosenow F, v. Stuckrad-Barre S. EEG-Pocketflyer, Börm Bruckmeier Verlag Grünwald 2010. ISDN 978-3-89862-660-0 (Auflage 30.000)

Hangen E, De Zio D, Bordi M, Zhu C, Dessen P, Caffin F, Lachkar S, Perfettini JL, Lazar V, Benard J, Fimia GM, Piacentini M, Harper F, Pierron G, Vicencio JM, Bénit P, de Andrade A, Höglinger G, Culmsee C, Rustin P, Blomgren K, Cecconi F, Kroemer G, Modjtahedi N. A brain-specific isoform of mitochondrial apoptosis-inducing factor: AIF2. Cell Death Differ. 2010;17:1155-66.

Hattemer K, Plate A, Heverhagen JT, Haag A, Keil B, Klein KM, Hermsen A, Oertel WH, Hamer HM, Rosenow F, Knake S. Determination of hemispheric dominance with mental rotation using functional transcranial doppler sonography and fMRI. J Neuroimaging 2010 in print.

Hauser V, Zangger P, Winter Y, Oertel WH, Kesselring J. Late sequela of whiplash injury with dis-section of cervical arteries. Eur Neurol 2010; 64: 214-218

Heidbrink C, Häusler SF, Buttmann M, Ossadnik M, Strik HM, Keller A, Buck D, Verbraak E, van Meurs M, Krockenberger M, Mehling M, Mittelbronn M, Laman JD, Wiendl H, Wischhusen J. Reduced cortisol levels in cerebrospinal fluid and differential distribution of 11beta-hydroxysteroid dehydrogenases in multiple sclerosis: Implications for lesion pathogenesis. Brain Behav Immun. 2010 Apr 10. [Epub ahead of print]

Henze T, Janzen RWC, Schumm F, Melms A, Sieb JP, Köhler W, Heidenreich F, Tackenberg B für den Ärztlichen Beirat der Deutschen Myasthenie-Gesellschaft (DMG), Weber-Schöndorfer C. Immuntherapie bei Myasthenia gravis und Lambert-Eaton Syndrom. Teil 1: Medikamentöse Immunsuppression, Akt Neurol 2010; 37: in press

Henze T, Janzen RWC, Schumm F, Melms A, Sieb JP, Köhler W, Heidenreich F, Tackenberg B für den Ärztlichen Beirat der Deutschen Myasthenie-Gesellschaft (DMG), Weber-Schöndorfer C. Immuntherapie bei Myasthenia gravis und Lambert-Eaton Syndrom. Teil 2: Intravenöse Immunglobuline und Plasmaaustauschverfahren, Akt Neurol 2010; 37: in press

Hermsen A, Rewif PS, Haag A., Bauer S, Hamer HM, Schramm J, Rosenow F. Hemispärotomie bei einer 17-jahrigen Patientin mit Sturge-Weber-Syndrom. Indikation und Follow-Up. Z. Epileptol 2010;23:259-63. (Case report)

Hoelscher S, Leinweber B, Hefter H, Reuner U, Guenther P, Weiss KH, Oertel WH, Moeller JC. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson Disease, Eur Neurol 2010; 64: 83-87

Högl B, Oertel WH, Stiasny-Kolster K, Geisler P, Beneš H, García-Borreguero D, Trenkwalder C, Poewe W, Schollmayer E, Kohnen R on behalf of the Rotigotine SP710 Study Group. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol 2010; 10(1): 86

Jauss M, Schütz HJ, Tanislav C, Misselwitz B, Rosenow F. Effect of daytime, weekday and year of admission on outcome in acute ischemic stroke patients treated with thrombolytic therapy. Eur. J Neurol. 2010; 17:555-61.

Kalbe E, Onur OA, Minnerop M, Reimann J, Althaus A, Ahmadzadehfar H, Dodel R, Strach K, Clemen CS, Herholz K, Haense C, Fink GR, Schröder R (2010) Early signs of VCP-related frontotemporal dementia: a neuropsychological, FDG-PET and fMRI study. J Neurol (Epub ahead of print)

Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, Tilz C, Trinka E. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2010.01423.x., online ahead.

Klein K M, Fritsch B, Rosenow F. Elektroenzephalogramm (EEG), evozierte Potentiale (EP). In Dodel R, Klockgether T (eds.) Roter Faden Neurologie. Wissenschaftliche Verlagsgesellschaft Stuttgart, 2010: 149-59

Knake S, Belke M, Menzler K, Pilatus U, Eggert KM, Oertel WH, Stamelou M, Höglinger GU. In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using track-based spatial statistics. Mov Disord 2010; 25(9): 1232-1238

Knake S, Heverhagen JH, Menzler K, Keil B, Oertel WH, Stiasny-Kolster K. Normal regional iron concentration in RLS measured by MRI. Nature Sci Sleep 2010; 2: 19-22

Knake S, Wehner T, Grant PE. Structural imaging of Mesial Temporal Lobe Epilepsy. In: The mesial temporal lobe epilepsies. Eds: Rosenow F, Lueders HO. 2010, in press

Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Klockgether T, Yekhlef F, Tison F, Daniels C, Deuschl G, Coelho M, Sampaio C, Bozi M, Quinn N, Schrag A, Mathias CJ, Fowler C, Nilsson CF, Widner H, Schimke N, Oertel W, Del Sorbo F, Albanese A, Pellechia MT, Barone P, Djaldetti R, Colosimo C, Meco G, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Rascol O, Kamm C, Gasser T, Siebert U, Poewe W, Wenning GK; on behalf of the EMSA-SG. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010; 25(15): 2604-2612
Krakow K, Sitzer M, Rosenow F, Steinmetz H, Foerch C. Predictors of Acute Poststroke Seizures. Cerebrovasc Dis. 2010;30:584-589.

Larisch A, Reuss A, Oertel WH, Eggert K. Does the Clinical Practice Guideline on Parkinson’s Disease change health outcomes? A cluster randomised controlled trial. J Neurol 2010 [Epub ahead of print]

Li G, Bauer S, Nowak M, Norwood B, Tackenberg B, Rosenow F, Knake S, Oertel WH, Hamer HM. Cytokines and epilepsy. Seizure - Eur J Epilepsy 2010, in press

Lünemann A, Tackenberg B, DeAngelis T, Barreira da Silva R, Messmer B, Vanoaica LD, Miller A, Apatoff B, Lublin FD, Lünemann JD, Münz C. Impaired IFN-g production and proliferation of Natural Killer cells in Multiple Sclerosis. Int Immunol 2010, in press
Lünemann JD, Tackenberg B, Stein A, Wandinger KP, Oertel WH, Wagner HJ, Münz C, Meisel H, Sommer N, Zipp F. Dysregulated Epstein-Barr virus infection in patients with CIDP. J Neuroimmunol 2010; 218(1-2):107-111

Menzler K, Belke M, Wehrmann E, Krakow K, Lengler U, Jansen A, Hamer HM, Oertel WH, Rosenow F, Knake S. Men and women are different: Diffusion tensor imaging reveals sexual dimorphism in the microstructure of the thalamus, corpus callosum and cingulum. Neuroimage. 2010 Nov 16

Menzler K, Chen X, Thiel P, Iwinska-Zelder J, Miller D, Reuss A, Hamer HM, Reis J, Pagenstecher A, Knake S, Bertalanffy H, Rosenow F, Sure U. Epileptogenicity of cavernomas depends on (archi-) cortical localization. Neurosurgery. 2010 Oct;67(4):918-24.

Menzler K, Iwinska-Zelder I, Shiratori K, Jaeger RK, Oertel WH, Hamer HM, Rosenow F, Knake S. Evaluation of MRI criteria (1.5 T) for the diagnosis of hippocampal sclerosis in healthy subjects. Epilepsy Res 2010;89:349-354.

Menzler K, Marcus Belke; Enno Wehrmann; Karsten Krakow, MD; Ulrike Lengler, MD; Andreas Jansen, MD; Hajo M Hamer, MD; Wolfgang H Oertel, MD; Felix Rosenow, MD; Susanne Knake, M. Men and women are different: Diffusion Tensor Imaging reveals sexual dimorphism in the microstructure of the thalamus, corpus callosum and cingulum Neuroimage in Druck.

Menzler, K, Chen X, Thiel P, Iwinska-Zelder J, Miller D, , Reuss A, Hamer HM, Reis J, Pagenstecher A, Knake S, Bertalanffy H, Rosenow F*, Sure U.* Epileptogenicity of Cavernomas depends on (Archi-) Cortical localization. Neurosurgery 2010;67:918-24.

Meyer B, Ringel F, Winter Y, Spottke A, Gharevi N, Dams J, Balzer-Geldsetzer M, Müller I, Klockgether T, Schramm J, Urbach H, Dodel R (2010) Health-Related Quality of Life in Patients with Subarachnoid Hemorrhage. Cerebrovascular Dis 30:423-31.

Moeller JC, Unger M, Stiasny-Kolster K, Oertel WH. Restless Legs Syndrome (RLS) and Parkin-son’s disease (PD) – related disorders or different entities ? J Neurol Sci 2010; 289: 135-137

Moldrich G, Lange, P, Strik H. Carcinoembryonic Antigen in the CSF of Cancer Patients – the value of intrathecal synthesis and correlation with IgA-diffusion dynamics. Acta Neurol Belg 2010, in press.

Mollenhauer B, Förstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int 2010; 107(39): 684-691

Mollenhauer B, Förstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Demenz mit Lewy-Körpern und Parkinson-Krankheit mit Demenz. Deutsche Ärzteblatt 2010; 107 (39): 685-691

Müller-Vahl K, Dodel I, Müller N, Münchau A, Reese JP, Balzer-Geldsetzer M, Dodel R, Oertel WH (2010) Health-related quality of life in patients with Gilles de la Tourette's syndrome. Mov Disord 25(3):309-314.

Mylius V, Knaack A, Haag A, Teepker M, Oertel WH, Thut G, Hamer H, Rosenow F. Effects of Paired-pulse Transcranial Magnetic Stimulation of the Motor Cortex on Perception of Experimentally Induced Pain. Clin J Pain 2010;26:617-623.

Mylius V, Moeller JC, Oertel WH. Ätiologie und Pathophysiologie des Restless Legs Syndroms. In: Bassetti C (Hrsg), Das RLS Syndrom. Uni-Med Verlag

Mylius V, Moeller JC, Strauch K, Oertel WH, Stiasny-Kolster K. No significance of the COMT val(158)met polymorphism in restless legs syndrome. Neurosci Lett 2010; 473(2): 151-154

Neyns B, D´Haeseleer M, van den Couter J, Rogier A, Strik H. The role of cytotoxic drugs in the treatment of central nervous system gliomas. Acta Neurol Belg 2010, 110(1): 1-14

Nölker C, Dodel R (2010) Therapieansätze zur Behandlung der Demenz bei neurologischen Erkrankungen / Therapeutic approaches for the treatment of cognitve dysfunction and dementia in neurological disorders. Nervenheilkunde 29(11):769-772.

Nowak M, Bauer S, Haag A, Cepok S, Li G, Tackenberg B, Norwood B, Oertel WH, Rosenow F, Hemmer B, Hamer HM. Interictal alterations of cytokines and leukocytes in patients with active epilepsy. Brain, Behavior and Immunity 2010, in press

Ocker M, Tackenberg B, Strik H. Fingolimod. Entwicklung von Signaltransduktions-hemmern für die Therapie der Multiplen Sklerose. Nervenheilkunde 2010; 29: in press

Oertel WH, Benes H, Garcia-Borreguero D, Hoegl B, Poewe W, Montagna P, Ferini-Strambi L, Sixel-Doering F, Trenkwalder C, Partinen M, Saletu B, Polo O, Fichtner A, Schollmayer E, Kohnen R, Cassel W, Penzel T, Stiasny-Kolster K. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010; 11(9): 848-856

Oertel WH, Kircher TTJ. The relationship of psychiatry and neurology. Nervenarzt 2010; 81(11): 1281-1288

Perske C; Nagel I, Nagel H, Strik H. CSF cytology – the ongoing dilemma to distinguish neoplastic and inflammatory lymphocytes. Diagn Cytopath 2010, in press.

Reese JP, Campenhausen S, Winter Y, Balzer-Geldsetzer M, Eggert K, Oertel WH, Dodel R (2010) Morbus Parkinson: Krankheitskosten und Versorgungssituation in Deutschland. Gesundheitswesen in press

Reese JP, Dodel R, Kolominsky-Rabas P (2010) Kapitel 8.10 Neurologie 382-387. Lehrbuch Versorgungsforschung. Hrsg. Pfaff, Neugebauer, Glaeske, Schrappe. Schattauer ISBN 978-3-7945-2797-7.

Reese JP, Winter Y, Balzer-Geldsetzer M, Bötzel K, Eggert K, Oertel WH, Dodel R, Campenhausen SV (2010) Parkinson's Disease: Cost-of-Illness in an Outpatient Cohort. Gesundheitswesen. 2010 Mar 12. [ahead of print]

Reich E, Engenhardt-Cabilic R, Rosenow F. Strahlentherapie bei arteriovenösen Malformationen- assoziierten Epilepsien. Übersicht zur aktuellen Studienlage. Z Epileptol 2010;23:238-43.

Reichmann H, Deuschl G, Riedel O, Spottke A, Förstl H, Henn F, Heuser I, Oertel W, Riederer P, Trenkwalder C, Dodel R, Wittchen HU. The German Study on the Epidemiology of Parkinson's Disease with Dementia (GEPAD): more than Parkinson. MMW Fortschr Med 2010; 152 Suppl 1: 1-6

Reif PS, Strzelczyk A, Hermsen A, Knake S, Hamer HM, Rosenow F. Filtersetting beim invasiven Video-EEG-Monitoring. Zeitschrift für Epileptologie 2010,1;1-5

Reif PS, Strzelczyk A, Ruegg S, Jacobs AH, Haag A, Hermsen A, Sure U, Knake S, Hamer HM, Strik H, Kramer G, Engenhart-Cabilic R, Rosenow F. Primary brain tumors and brain metastases: Symptomatic epilepsy and driving ability - systematic review and expert opinion. Nervenarzt. 2010; Epub ahead of print

Reimann J, Schnell S, Schwartz S, Kappes-Horn K, Dodel R Bacher M (2010) Macrophage migration inhibitory factor (MIF) in normal human skeletal muscle and inflammatory myopathies. Journal of Neuropathology and Experimental Neurology 69(6):654-62.

Respondek G, Decker S, Steinmeyer L, Oertel WH, Höglinger GU. Differenzialdiagnosen der Parkinson-Krankheit: aktuelle Konsensuskriterien und Ausblicke. Fortschr Neurol Psychiat 2010; 78 (Suppl 1): S51-58

Respondek G, Decker S, Steinmeyer L, Oertel WH, Höglinger GU. Differential diagnosis of Parkinson's disease: current consensus criteria and outlook. Fortschr Neurol Psychiatr. 2010;78 Suppl 1:S8-15.

Riedel O, Heuser I, Klotsche J, Dodel R, Wittchen HU, (+ GEPAD study group - Oertel W). Occurrence risk and structure of depression in Parkinson´s disease with and without dementia: results from the GEPAD study. J Geriatr Psychiatry Neurol 2010; 23(1): 27-34

Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2010) Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol. 257(7):1073-82.

Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K. German Tolcapone Study GroupReplacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Clin Neuropharmacol. 2010; 33:142-50.

Rodrigues A, Geldsetzer F, Holdorff B, Kielhorn F, Balzer-Geldsetzer M, Oertel WH, Hurtig H, Dodel R (2010) Who was the man, who discovered the “Lewy Bodies”?. Mov Disord 25(12):1765-73.

Rodrigues E Silva AM, Geldsetzer F, Holdorff B, Kielhorn FW, Balzer-Geldsetzer M, Oertel WH, Hurtig H, Dodel R. Who was the man, who discovered the “Lewy Bodies”? Mov Disord 2010; 25(12): 1765–1773

Rosenow F, Knake S. Status epilepticus: Adults. In : Handbook of Clinical Neurophysiology: Series Epiepsy. Eds: W. Theodore, H. Stefan. 2010 in press

Rosenow F, Reif PS, Haag A, Schmidt K, Strik H. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology. 2010, 74(16): 1330-1

Rosenow F, Werhahn K. Degenerative Erkrankungen mit Epilepsie. In Dodel R, Klockgether T (eds.) Roter Faden Neurologie. Wissenschaftliche Verlagsgesellschaft Stuttgart, 2010: 335-337

Rosenow F. Anfallserkrankungen. In Dodel R, Klockgether T (eds.) Roter Faden Neurologie. Wissenschaftliche Verlagsgesellschaft Stuttgart, 2010: 323-35

Rosenow F. Nicht-epileptische Anfälle. In Dodel R, Klockgether T (eds.) Roter Faden Neurologie. Wissenschaftliche Verlagsgesellschaft Stuttgart, 2010: 337-9

Rösler TW, Arias-Carrión O, Höglinger GU. Zonisamide: aspects in neuroprotection. Exp Neurol. 2010;224:336-9.

Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schröder R, Heuss D, Vielhaber S, Mylius V, Kiefer R, Schrank B, Oertel WH, Dodel R. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol 2010; 257(1): 15-23

Seitz F, Eienbröker C, Tackenberg B. Remission unter Natalizumab einer hochaktiven schubförmigen MS mit Beginn im Kindesalter. Nervenheilkunde 2010; 9a (im Druck).
Siebert U, Bornschein B, Dams J, Eggert K, Herting B, Gasser T, Volkmann J, Bötzel K, Kupsch A, Kraus P, Oertel WH, Wittenberg E, Dodel R (2010) Independent Impact of Dyskinesias on Health-Related Quality of Life in Patients with Parkinson's Disease. J Neurol Neurosur Psy (in press)

Stamelou M, Christ H, Reuss A, Oertel WH, Höglinger GU. Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Mov Disord. In press.

Stamelou M, De Silva R, Arias-Carrion O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010; 133(6): 1578-1590

Stamelou M, Knake S, Oertel WH, Höglinger GU. Magnetic resonance imaging in progressive supranuclear palsy. Journal of Neurology. In press.

Stangel M, Gold R für die IVIG-Konsensusgruppe (…, Tackenberg B, …). Einsatz intravenöser Immunglobuline in der Neurologie. Nervenarzt 2010; DOI 10.1007/s00115-010-3059-8.

Strik H, Prömmel P. Diagnosis and individualized therapy of neoplastic meningitis. Expert Review of Anticancer Therapy, 2010, 10(7):1137-48

Strik H. Neoplasien. In: Dodel, Klockgether. Neurologie. Wissenschaftliche Verlagsgesellschaft Stuttgart 2010

Strik H, Prömmel P. Meningeosis neoplastica: Diagnostik und individualisierte Therapie (CME Fortbildung). Der Nervenarzt 2010, 81(2):229-41

Strzelczyk A, Haag A, Raupach H, Herrendorf G, Hamer HM, Rosenow F. Prospective evaluation of a post-stroke epilepsy risk scale. J Neurol 2010;257:1322-6.

Strzelczyk A, Nowak M, Bauer S, Reif PS, Oertel WH, Knake S, Hamer HM, Rosenow F. Localizing and lateralizing value of ictal flatulence. Epilepsy Behav. 2010;17:278-82.

Strzelczyk A, Sure U, Rosenow F. Teaching NeuroImages: spontaneous asymptomatic occlusion of a cerebral arteriovenous malformation. Neurology. 2010 ;74:e105. (Teaching Neuroimage)

Tackenberg B, Nimmerjahn F, Lünemann JD. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J Clin Immunol 2010; 30(S1): S65-69.

Tackenberg, Die zelluläre Immunantwort und ihre therapiebedingten Modulation bei neuromuskulären Autoimmunerkrankungen, Habilitationsschrift, Marburg 2010

Teepker M, Hoetzel J, Timmesfeld N, Reis J, Mylius V, Haag A, Oertel W, Rosenow F, Schepel-mann K. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia. 2010; 30(2): 137-144

Unger M, Hattemer K, Möller JC, Schmittinger K, Mankel K, Eggert K, Strauch K, Tebbe JT, Keil B, Oertel WH, Heverhagen JT, Knake S. Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson’s disease. Mov Disord 2010; 25: 623-628

Unger M, Menzler K, Schmittinger K, Moeller C, Mekle K, Eggert KM, Tebbe J, Keil B, Oertel WH, Heverhagen JH; Knake S. Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson’s disease. Movement Disorders 2010, in press

Unger MM, Belke M, Katja Hattemer K, Stiasny-Kolster K, Keil B, Rosenow F, Heverhagen JT, Diederich NJ, Mayer G, Möller JC, Oertel WH, Susanne Knake S. In vivo demonstration of selective white matter pathology in patients with idiopathic rapid eye movement (REM) sleep behaviour disorder (RBD): a DTI study using TBSS. Sleep 2010; 33(6):767-73.

Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, Rosenow F, Diederich NJ, Mayer G, Möller JC, Oertel WH, Knake S. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 2010; 33(6): 767-773

von Campenhausen S, Winter Y, Silva AR, Sampaio C, Ruzicka E, Barone P, Poewe W, Guekht A, Mateus C, Pfeiffer KP, Berger K, Skoupa J, Bötzel K, Geiger-Gritsch S, Siebert U, Balzer-Geldsetzer M, Oertel WH, Dodel R, Reese JP (2010) Costs of illness and care in Parkinson's Disease: An evaluation in six countries. Eur Neuropsychopharmacol (Epub ahead of print)

Von Reichmann H, Deuschl G, Riedel O, Spottke A, Förstl H, Henn F, Heuser I, Oertel W, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2010) The German Study on the Epidemiology of Parkinson's Disease with Dementia (GEPAD): more than Parkinson. MMW Fortschr Med. 152 Suppl 1:1-6. German

Winter Y, Balzer-Geldsetzer M, Spottke A, Reese JP, Baum E, Klotsche J, Rieke J, Simonow A, Eggert K, Oertel WH, Dodel R (2010) Longitudinal Study of the Socioeconomic Burden of Parkinson’s Disease in Germany. Eur J Neurol 17(9):1156-63.

Winter Y, Balzer-Geldsetzer M, von Campenhausen S, Spottke A, Eggert K, Oertel WH, Dodel R (2010) Trends in resource utilization for Parkinson's disease in Germany. J Neurol Sci. 294(1-2):18-22.

Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J, Oertel WH, Dodel R, Gusev E (2010) Incidence of Parkinson's disease and atypical Parkinsonism: Russian population-based study. Mov Disord 25(3):349-356.

Winter Y, Campenhausen S, Reese JP, Balzer-Geldsetzer M, Longo K, Spiga G, Bötzel K, Eggert K, Oertel WH, Dodel R, Barone P (2010) Costs of Parkinson’s disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study. Neurodegenerative Dis 7:365-372

Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R, Heuss D, Vielhaber S, Tackenberg B, Mylius V, Reese JP, Kiefer R, Schrank B, Oertel WH, Dodel R (2010) Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 257(9):1473-81.

Winter Y, von Campenhausen S, Brozova H, Skoupa J, Reese JP, Bötzel K, Eggert K, Oertel WH, Dodel R, Ruzicka E. Costs of illness of Parkinson’s disease in Eastern Europe: a Czech cohort study. Parkinsonism Rel Disord 2010; 16(1): 51-56

Winter Y, von Campenhausen S, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Bötzel K, Oertel WH, Dodel R, Poewe W. Social and clinical determinants of quality of life in Parkinson’s disease in Austria. a cohort study. J Neurol 2010; 257(4): 638-645

Winter Y, von Campenhausen S, Popov G, Reese JP, Balzer-Geldsetzer M, Kukshina A, Zhukova TV, Bertschi N, Boetzel K, Gusev E, Oertel WH, Dodel R, Guekht A. Social and clinical determinants of quality of life in Parkinson’s disease in a Russian cohort study. Parkinsonism Rel Disord 2010; 16(4): 243-248

Winter Y, von Campenhausen S, Reese JP, Balzer-Geldsetzer M, Longo K, Spiga G, Boetzel K, Eggert K, Oertel WH, Dodel R, Barone P. Costs of Parkinson’s disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegen Diseases 2010; 7(6): 365-372

Woitalla D, Braak H, de Tredici KD, Hagenah J, Oertel W, Berg D. Transcraniel ultrasound in the differential diagnosis of Parkinson’s disease. Fortschr Neurol Psychiat 2010; 78 (Suppl 1): S25-30


2009

Agbo DB, Neff F, Seitz F, Binder C, Oertel WH, Bacher M, Dodel R (2009) Immunization as Treatment for Parkinson’s Disease. In: Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra. G. DiGiovanni, V. DiMatteo, E. Esposito (Hrsg). Springer-Verlag. 311-315

Antonini A, Dodel R, Odin P, Lorrain M, Volkmann J, Reichmann H, Storch A, Poewe W (2009) Im Fokus: L-Dopa-Pumpe, Apomorphin-Pumpe, Tiefe Hirnstimulation. Therapiemöglichkeiten beim fortgeschrittenen Morbus Parkinson. Thieme Drug Report 4:1-11.

Arias-Carion O, Yamada E, Freundlieb N, Djufri M, Maurer L, Hermanns G, Ipach B, Chiu W-H, Steiner C, Oertel WH, Höglinger GU. Neurogenesis in substantia nigra of Parkinsonian brains ? In: In Di Giovanni G, Di Matteo V, Esposito E (eds), “Birth, life and death of dopaminergic neurons in the substantia nigra”, Chapter 26, Wien New York J Neural Transm Suppl 2009; 73: 279-285

Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M (2009) The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 115(10):2031-40.

Bach JP, Oertel WH, Dodel R, Jessen F (2009) Treatment of hypersexuality in Parkinson’s disease with carbamazepine – A case report. Mov Disord 24(8):1241-2.

Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, Henriksen G, Behe M, Dodel R. Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer’s disease. Neurosci Lett 2009; 449 (3): 240-245

Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, Popp J, Noelker C, Reese JP, Al-Abed Y, Dodel R (2009) The Role of Macrophage Migration Inhibitory Factor in Alzheimer’s Disease. Mol Med 16(3-4):116-21.

Bartnik D, Funke SA, Andrei-Selmer LC, Bacher M, Dodel R, Willbold D (2009) Differently Selected d-Enantiomeric Peptides Act on Different Abeta Species. Rejuvenation Res 13(2-3):202-5.

Bauer S, Cepok S, Todorova-Rudolph A, Nowak M, Koeller M, Lorenz R, Oertel WH, Rosenow F, Hemmer B, Hamer HM. Etiology and site of temporal lobe epilepsy influence postictal cytokine release. Epilepsy Res 2009; 86(1): 82-86

Bodden ME, Dodel R, Kalbe E (2009) Theory of mind in Parkinson’s disease and related basal ganglia disorders: A systematic review. Mov Disord 25(1):13-27.

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 2009;27:509-518.

Buerk K, Farecki ML, Lamprecht G, Roth G, Decker P, Weller M, Rammensee HG, Oertel W. Neurological symptoms in patients with biopsy proven celiac disease. Mov Disord 2009; 24(16):2358-2362.

Campenhausen S, Winter Y, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Geiger-Gritsch S, Bötzel K, Siebert U, Oertel WH, Dodel R, Poewe W (2009) Cost of illness and health service patterns in Morbus Parkinson in Austria. Wien Klin Wochenschr 121(17-18):574-82

Dodel R, Bacher M (2009) Innovative treatment approaches for Alzheimer's disease. Immunotherapy. Nervenarzt 79 Suppl 3:149-57; quiz 158.

Dodel R, Bodden M (2009) State of the Art – Alzheimer-Demenz. PharmaFokus ZNS 6. Jahrgang Sep 2009: 44-50.

Dodel R, Schrag A (2009) V.R. Preedy, R.R. Watson (Hrsg) Health-related Quality of Life in Movement Disorders. Handbook of Disease Burdens and Quality of Life Measures, Springer Verlag.

Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, Trenkwalder C, Sixel-Döring F, Herting B, Kamm C, Gasser T, Sawires M, Geser F, Köllensperger M, Seppi K, Kloss M, Krause M, Daniels C, Deuschl G, Böttger S, Naumann M, Lipp A, Gruber D, Kupsch A, Du Y, Turkheimer F, Brooks DJ, Klockgether T, Poewe W, Wenning G, Schade-Brittinger C, Oertel WH, Eggert K. (2009) Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord 25(1):97-107.

Eggert K, Larisch A, Dodel R, Bormann C, Oertel WH (2009) Awareness and Knowledge of the Clinical Practice Guideline on Parkinson’s Disease among German Neurologists. Eur Neurol. 61(4) :216-222

Ehret R, Balzer-Geldsetzer M, Reese JP, Dodel I, Becker E, Christopher A, Friedrich H, Kraemer S, Lüer W, Müngersdorf M, Puzich R, Rohr A, Schultes-Platzek I, Siefjediers V, Tiel-Wilck K, Oertel WH, Dodel R (2009) Direct costs for Parkinson’s treatment in private neurology practices in Berlin. Nervenarzt 80(4): 452-8.

Eienbröker C, Gellert K, Sommer N, Oertel WH, Tackenberg B. Diagnose und Therapie der Myasthenia gravis. INFO Neurologie & Psychiatrie 2009; 11: 32-41.

Eienbröker C, Tackenberg B. Deescalation to Interferon- 1b after mitoxantrone and natalizumab. Akt Neurol 2009; 36: S277-S280.

Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E. Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Disord 2009; 24(5): 655-661

Gold R, Hartung HP, Hohlfeld R, et al. für die AG Moderne Immuntherapien der MS (...,Tackenberg B,...). Therapie der Multiplen Sklerose mit monoklonalen Antikörpern. Ergebnisse und Empfehlungen einer Arbeitstagung des Ärztlichen Beirates der Deutschen Multiple Sklerose Gesellschaft, Akt Neurol 2009; 36: 334-344.

Haag A, Moeller N, Knake S,H ermsen A, Oertel WH, Rosenow F, Hamer HM. Language lateralization in children using functional transcranial Doppler sonography. Dev Med Child Neurol 2009; [Epub ahead of print]

Halász P; Kälviäinen R; Mazurkiewicz-Beldzińska M; Rosenow F; Doty P, Hebert D; Sullivan T; on behalf of the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53.

Hamer HM, Hägele U, Leverkus F, Schmidt D. Praktische Erfahrungen mit Pregabalin als Zusatztherapie bei fokaler Epilepsie: eine Anwendungsbeobachtung. Akt Neurol 2009;36:437-442.

Hamer HM. Epileptische Anfälle und Epilepsien nach „Schlaganfall“. Nervenarzt 2009; 80:405–414.

Hattemer K, Plate A, Heverhagen J, Haag A, Keil BR, Klein KM, Hermsen A, Oertel WH, Hamer HM, Rosenow F, Knake S. Determination of hemispheric dominance with mental rotation using functional transcranial Doppler sonography and fMRI. Epilepsy Behav 2009; epub ahead of print.

Hattingen E, Lanfermann H, Menon S, Neumann-Haefelin T, DuMesnil de Rochement R, Stamelou M, Höglinger GU, Pilatus U. Combined 1H- and 31P-MR spectroscopic imaging: Impaired energy metabolism in severe carotid stenosis and changes upon treatment, MAGMA, 2009;22:43-52.

Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, Franke A, Muhle H, de Kovel C, Baker C, von Spiczak S, Kron KL, Schmitz B, Steinich I, Kleefuß-Lie A, Leu C, Gaus V, Klein KM, Reif PS, Rosenow F, Weber Y, Lerche H, Zimprich F, Urak L, Fuchs K, Feucht M, Genton P, Thomas P, Visscher F, de Haan GJ, Møller RS, Hjalgrim H, Luciano D, Wittig M, Nothnagel M, Elger CE, Nürnberg P, Romano C, Malafosse A, Koeleman BPC, Lindhout D, Stephani U, Schreiber S, Eichler EE, Sander T. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nature Genetics 2009;41:160-2.

Hermann A, Suess C, Fauser M, Kanzler S, Witt M, Fabel K, Schwarz J, Höglinger GU, Storch A. Rostro-caudal gradual loss of cellular diversity within the periventricular regions of the ventricular system, Stem Cells, 2009;27:928-41.

Hoffmann A., Buhk JH., Strik HM. Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C with dose-dense temozolomide. Anticancer Res. 2009, 29(2): 5191-5.

Höllerhage M, Matusch A, Champy P, Lombès A, Ruberg M, Oertel WH, Höglinger GU. Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies. Exp Neurol. 2009;220:133-42.

Jauss M, Oertel WH, Allendoerfer J, Misselwitz M, Hamer H. Bias in request for medical care and impact on outcome during office and non-office hours in stroke patients. Eur J Neurol, 2009;16:1165-1167.

Jauss M, Sitzer M, Stolz E, Misselwitz B, Rosenow F. Lack of increase of cerebrovascular events during German World Cup soccer games in 2006. J Neurol. 2009;256:863-6.

Kallenberg K, Bock HC, Helms G, Jung K, Wrede A, Buhk JH, Giese A, Frahm J, Strik H, Dechent P, Knauth M. Proton MR Spectroscopy Reveals Elevated Myo-Inositol and Glutamine in the Contralateral Cerebral Hemisphere of Patients with Untreated Glioblastoma Multiforme. Radiology 2009, 253(3): 805-12.

Knake S, Hamer HM, Rosenow F. Reply to the Letter to the Editor regarding "Status epilepticus - a critical review" - Knake S, Hamer HM, Rosenow F. Epilepsy Behav 2009;15:10-4. Epilepsy Behav. 2009 Aug 14. [Epub ahead of print] No abstract available.
Knake S, Hamer HM, Rosenow F. Status epilepticus: A critical review. Epilepsy Behav 2009;15:10-4.

Knake S, Salat DH, Halgren E, Halko M, Greve DN, Grant PE. Changes in white matter microstructure and patients with temporal lobe epilepsy due to hippocampal sclerosis. Epileptic Disord 2009;11:244-250

Küster O, Simon P, Mittelbronn M, Tabatabai G, Hermann C, Strik H, Dietz K, Roser F, Meyermann R, Schittenhelm J. Erythropoietin receptor is expressed in meningiomas and lower levels are associated with tumour recurrence. Neuropath Appl Neurobiol 2009, 35(6): 555-65

Larisch A, Oertel WH, Eggert K. Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson’s Disease. A national survey of German neurologists in private practice. J Neurol 2009; 256(10):1681-1688

Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, Höglinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, Melquist S, Oertel W, Otto M, Paviour D, Reum T, Saint-Raymond A, Steele JC, Tolnay M, Tumani H, van Swieten JC, Vanier MT, Vonsattel JP, Wagner S, Wszolek ZK; Reisensburg Working Group for Tauopathies With Parkinsonism. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 2009; 16(3): 297-309

Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, Benamer HT, Kemp P, Burn D, Tolosa E, Kulisevsky J, Cunha L, Costa D, Booij J, Tatsch K, Chaudhuri KR, Ulm G, Pogarell O, Höffken H, Gerstner A, Grosset DG. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [(123)I] FP-CIT SPECT. Mov Disord 2009; 24 (4): 500-508

Matusch A, Depboylu C, Palm C, Wu B, Höglinger GU, Schäfer MK, Becker JS. Cerebral bioimaging of Cu, Fe, Zn, and Mn in the MPTP mouse model of Parkinson's disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). J Am Soc Mass Spectrom. 2010;21:161-71.

Moeller JC, Unger M, Stiasny-Kolster K, Kaussner Y, Penzel T, Oertel WH, Hemmeter U. Continuous sleep EEG monitoring in PD patients with and without sleep attacks. Parkinsonism Relat Disord 2009; 15 (3): 238-241

Mylius V, Engau I, Teepker M, Stiasny-Kolster K, Schepelmann K, Oertel WH, Lautenbacher S, Moeller JC. Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol Neurosurg Psychiat 2009; 80 (1): 24-28

Mylius V, Gerstner A, Peters M, Prokisch H, Leonhardt A, Hellwig D, Rosenow F. Low-frequency rTMS of the premotor Cortex reduces complex movement patterns in a patient with Pantothenate Kinase-Associated Neurodegenerative Disease (PKAN). Neurophysiologie Clinique/Clinical Neurophysiology 2009;39:27-30.

Nedelmann M, Stolz E, Gerriets T, Baumgartner RW, Malferrari G, Seidel G, Arsovska A, Bartels E, Baumgartner R, Droste D, Eggers J, Eyding J, Gahn G, Georgiadis D, Gerriets T, Goertler M, Hamer H, Hoksbergen AW, Kaps M, Kloetzsch C, Kozera G, Krejza J, Larrue V, Malferrari G, Maeurer M, Minematsu K, Perren F, Postert T, Ringelstein EB, Ritter M, Schlachetzki F, Schmitt E, Seidel G, Skoloudik D, Stolz E, Sztajzel R, Tegeler C, von Reutern GM, Wardlaw J, Wunderlich M, Kaps M. Consensus recommendations for transcranial color-coded duplex sonography for the assessment of intracranial arteries in clinical trials on acute stroke. Stroke 2009;40:3238-3244.

Reese JP, Balzer M, Dodel R (2009) Alzheimer-Erkrankung: gesundheits-ökonomische Aspekte. Neuro aktuell 178:20-22

Riedel O, Heuser I, Klotsche J, Dodel R, Wittchen HU (2009) Occurrence Risk and Structure of Depression in Parkinson Disease With and Without Dementia: Results From the GEPAD Study. J Geriatr Psychiatry Neurol 23(1):27-34

Rissling I, Strauch K, Höft C, Oertel WH, Moeller JC. Haplotype analysis of the engrailed-2 gene in young-onset Parkinson’s disease. Neurodegen Dis 2009; 6(3): 102-105

Rosenow F, Hamer HM, Klein KM. Gewichtsveränderungen unter Antiepileptika.. Zeitschrift für Epileptologie 2009;22:163-9

Röskam S, Neff F, Schwarting R, Bacher M, Dodel R (2009) APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks. Neurosci Biobehav Rev 34(4):487-99.

Schepelmann K, Dodel R (2009) Krankheitskosten in Deutschland – Neuromuskuläre Erkrankungen. Neuro aktuell 6/09 Nr. 183

Schmidt D, Stefan H, Hamer HM, Runge U, Noachtar S. Moderne medikamentöse Epilepsietherapie im Alter: ein kurzer kritischer Überblick mit Empfehlungen. Nervenheilkunde 2009;28:53–58.

Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Gasser T. SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol 2009; 65(5): 610-614

Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, Meyer B, Al-Abed Y, Balakrishnan K, Reese JP, Bacher M (2009) Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer 9(1):464.

Schrag A, Spottke A, Quinn NP, Dodel R (2009) Comparative responsiveness of Parkinson’s disease scales to change over time. Mov Disord 24(6):813-8.

Stamelou M, Matusch A, Elmenhorst D, Hurlemann R, Eggert KM, Zilles K, Oertel WH, Höglinger GU, Bauer A. Nigrostriatal upregulation of 5-HT(2A) receptors correlates with motor dysfunction in progressive supranuclear palsy. Mov Disord 2009; 24(8): 1170-1175

Stamelou M, Pilatus U, Reuss A, Magerkurth J, Eggert KM, Knake S, Ruberg M, Schade-Brittinger C, Oertel WH, Höglinger GU. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy, J Cerebral Blood Flow Metabolism, 2009;29:861-70.

Stiasny-Kolster K, Möller JC, Heinzel-Gutenbrunner M, Baum E, Ries V, Oertel WH. Validation of the restless legs syndrome screening questionnaire (RLSSQ). Somnologie 2009; 13: 37-42

Strik H, Prömmel P. Diagnostik und individualisierte Therapie der Meningeosis neoplastica (CME Fortbildung). Der Onkologe 2009, 15(5): 527-40

Tackenberg B, Jelcic I, Baerenwaldt A, Münz C, Oertel WH, Sommer N, Nimmerjahn F, Lünemann J. Impaired inhibitory Fcγ receptor IIB expression on B cells in CIDP. Proc Natl Acad Sci U S A 2009; 106: 4788-4792.

Tackenberg B, Schlegel K, Happel M, Eienbröker C, Gellert K, Oertel WH, Meager A, Willcox N, Sommer N. Expanded TCR Vβ subsets of CD8+ T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients. J Neuroimmunol 2009; 216: 85-91.

Teepker M, Munk K, Mylius V, Haag A, Moeller JC, Oertel WH, Schepelmann K. Serum concentration of s100b and NSE in migraine. Headache 2009; 49 (2): 245-252

Unger MM, Möller JC, Ohletz T, Stiasny-Kolster K, Oertel WH, Mayer G. Transcranial midbrain sonography in narcoleptic subjects with and without concomitant REM sleep behaviour disorder. J Neurol 2009; 256(6): 874-877

Von Campenhausen S, Winter Y, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Geiger-Gritsch S, Bötzel K, Siebert U, Oertel WH, Dodel R, Poewe W. Krankheitskosten und Versorgungssituation bei Morbus Parkinson – eine Analyse in Österreich (Cost of illness and health service patterns in Morbus Parkinson in Austria). Wien Klin Wochenschr 2009; 121: 574-582

Wehner T, Bauer S, Hamer HM, Hattemer K, Immisch I, Knake S, Nowak M, Reif PS, Strzelczyk A, Rosenow F. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav. 2009;16:423-5.

Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease. Drug Des Devel Ther 2009; 2: 245-254

Winter Y, Campenhausen S, Brozova H, Skoupa J, Reese JP, Bötzel K, Eggert K, Oertel WH, Dodel R, Ruzicka E (2009) Cost of illness of Parkinson’s disease in Eastern Europe: A Czech cohort study. Parkinsonism Relat Disord. 16(1):51-56.

Winter Y, Campenhausen S, Popov G, Reese JP, Klotsche J, Boetzel K, Gusev E, Oertel WH, Dodel R, Guekht A (2009) Costs of Illness in a Russian Cohort of Patients with Parkinson's Disease. Pharmacoeconomics 27(7):571-584.

Winter Y, von Campenhausen S, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Bötzel K, Oertel WH, Dodel R, Poewe W (2009) Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. J Neurol 257(4):638-45.

Winter Y, von Campenhausen S, Popov G, Reese JP, Balzer-Geldsetzer M, Kukshina A, Zhukova TV, Bertschi N, Bötzel K, Gusev E, Oertel WH, Dodel R, Guekht A (2009) Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study. Parkinsonism Relat Disord 16(4):243-8.

Winter Y, Wolfram C, Schaeg M, Reese JP, Oertel WH, Dodel R, Back T (2009) Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol. 256(6):954-63.

Wöhr M, Kehl M, Borta A, Schänzer A, Schwarting RK, Höglinger GU. New insights into the relationship of neurogenesis and affect: tickling induces hippocampal cell proliferation in rats emitting appetitive 50-kHz ultrasonic vocalizations. Neuroscience. 2009;163:1024-30.

Zhou H, Miller D, Schulte DM, Benes L, Rosenow F, Bertalanffy H, Sure U. Transsulcal approach supported by navigation-guided neurophysiological monitoring for resection of paracentral cavernomas. Clin Neurol Neurosurg. 2009;111:69-78.



2008

Althaus A, Arránz Becker O, Spottke A, Dengler R, Schneider F, Kloss M, Eggert K, Oertel WH, Dillmann U, Herting B, Classen J, Dodel R (2008) Frequency and treatment of depressive symptoms in a Parkinson's disease registry. Parkinsonism Relat Disord 14(8):626-32

Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Hoeglinger GU, Oertel WH, Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and -synuclein-deleted mice. Exp Neurol 2008; 210: 182-193

Bach JP, Rinn B, Meyer B, Dodel R, Bacher M (2008) Role of MIF in inflammation and tumorigenesis. Oncology 75(3-4):127-33

Bach JP, Sommer N, Möller JC, Oertel WH, Dodel R, Gasser T (2008) Parkinson's syndrome in a young patient with Klinefelter's syndrome -A case report. Mov Disord 23(5):771-2.

Bacher M, Depboylu C, Du Y, Noelker C, Staufenbiel M, Behr T, Henriksen G, Behe M, Dodel R (2008) Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid antibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett. 449(3):240-5.

Bacher M, Dodel R, Aljabari B, Keyvani K, Marambaud P, Kayed R, Glabe C, Goertz N, Hoppmann A, Sachser N, Klotsche J, Schnell S, Lewejohann L, Al-Abed Y (2008) CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer’s disease. J Exp Med. 205(7): 1593-9.

Balzer-Geldsetzer M, Amelung G, Dodel R, Meier B. Innovative Konzepte im Versorgungsmanagement von ZNS-Patienten. Hrsg. Amelung, Bergmann, Falkai, Hauth, Jaleel, Meier, Reichmann, Roth-Sackenheim. Kapitel 3: Versorgungssituation von Patienten mit neurologischen Erkrankungen in Deutschland. Medizinisch Wissenschaftliche Verlagsgesellschaft.

Bauer S, Knake S, Haag A, Hermsen A, Strzelczyk A, Hamer HM, Rosenow F. Seizures induced by the sight of moving water. Epileptic Dis 2008;10:49-52.

Bauer S, Köller M, Cepok S, Todorova-Rudolph A, Nowak M, Nockher A, Lorenz R, Tackenberg B, Oertel WH, Rosenow F, Hemmer B, Hamer HM. NK and CD(+4) T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol 2008; 211: 370-377
Dejaegere T, Serneels L, Schäfer MK, Van Biervliet L, Horré K, Depboylu C, Alvarez-Fischer C, Höglinger GU, D’Hooge R, De Strooper B. Deficiency of Aph1B/C g-secretase disturbs NRG1 cleavage and sensorimotor gating which can be reversed with antipsychotic treatment. Proc Natl Acad Sci U S A, 2008;105:9775-80.

Dodel R (2008) Dementia. Capital 2.2.3: 32-37. The Treatment of Advanced Parkinson’s Disease/Jost W. UNI-MED Science Verlag.

Dodel R, Bach JP, Oertel WH (2008) Geist und Seele in Mitleidenschaft. Ärztliche Praxis Neurologie und Psychiatrie 6/2008 : 39-45.

Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, Oechsner M, Jost W, Reichmann H, Schulz JB (2008) Lewy body dementia and Parkinson’s disease with dementia. J Neurol 255(5):34-43.

Dodel R, Handbook of Disease Burdens and Quality of Life Measures. Kapitel: Health-related Quality of Life in Movement Disorders (2008) Springer Verlag.

Dodel R, Reese, JP, Balzer M (2008) The Economic Burden of Parkinson’s Disease. European Neurological Review Vol. 3 Issue 2 Supplement : III Int. Forum on Advanced Parkinson’s Disease : 11-14.

Dodel R, Schneider F, Spieker S (2008) Depression. Capital 2.2.2: 31-36. The Treatment of Advanced Parkinson’s Disease/Jost W. UNI-MED Science Verlag.

Dodel R, Siebert U, Wasem J (2008) Grundlagen der Neuro-Psychopharmakologie. Hrsg. Riederer, Laux. Kapitel: Gesundheits-ökonomische Bewertungen, Springer Verlag.

Dodel R, Siebert U, Wasem J (2008) Kapitel: Gesundheitsökonomische Bewertungen. Neuro-Psychopharmaka Band 1 Springer Verlag.

Dodel R, The Status of health in the European Union: Towards a healthier Europe. Report im Rahmen des Eugloreh-Projektes 2007

Dorst J, Haag A, Knake S, Oertel WH, Hamer HM, Rosenow F. Functional transcranial Doppler Sonography and a mental rotation paradigm identify eloquent cortical areas of the non-dominant hemisphere. Brain Cogn 2008 Oct;68(1):53-8.

Eggert K, Reese JP, Oertel WH, Dodel R (2008) Cost Effectiveness of Pharmacotherapies in Early Parkinson’s Disease. CNS Drugs 22(10) :841-60.

Eggert K, Schrader Ch, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel WH, Odin P. Continuous jejunal levodopa infusion in patients with advanced Parkinson’s disease: Practical aspects and outcome of motor and non-motor complication. Clin. Neuropharmacol 2008; 31: 151-166

Eggert KM, Deuschl G, Gasser T, Oertel WH, Arnold G, Baas H, Dodel R, Mehdorn HM, Przuntek H, Reichmann H, Riederer P, Spieker S, Trenkwalder C im Namen des Kompetenznetz Parkinson. Leitlinien in der Neurologie Therapie- Parkinson-Syndrome. In: Diener C, Hacke W (Hrsg), Leitlinien Neurologie, 3. Auflage. Thieme Verlag 2008

Eggert KM, Oertel WH, Reichmann H, Arnold G, Baas H, Berg D, Braune St, Deuschl G, Dodel R, Gasser T, Gerlach M, Höglinger G, Jost W, Mehdorn HM, Müngersdorf M, Przuntek H, Reuther P, Riederer P, Schulz J, Spieker S, Storch A, Tatsch K, Trenkwalder C im Namen des Kompetenznetzes Parkinson. Leitlinien in der Neurologie - Parkinson-Syndrome. In: Diener C, Hacke W (Hrsg), Leitlinien Neurologie, 4. Auflage. Thieme Verlag 2008: 82-112

Eggert KM, Reese JP, Oertel WH, Dodel R. Cost effectiveness of pharmacotherapies in early Parkinson’s disease. CNS Drugs 2008; 22: 841-860

Eisensehr I, Karlbauer G, Stiasny-Kolster K, Oertel W, Trenkwalder C. Diagnose und Therapie des RLS. In : Restless Legs Syndrom. Informationsbuch und Ratgeber für behandelnde Ärzte und Betroffene. Deutsche Restless Legs Vereinigung e.V (Hrsg). 4. Auflage, RLS e.V., 2008, pp. 14-28

Fogel W, Oertel WH. Basalganglienerkrankungen in der Intensivmedizin. In: Schwab S, Schellinger P, Werner C, Unterberg A, Hacke A (Hrsg), Neurointensiv. Kapitel 38.6, Springer Heidelberg, pp 665-671

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, Lewitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, Lapelle N; for the Movement Disorder Society UPDRS Revision Task Force (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) : Scale presentation and clinimetric testing results. Mov Disord. 23(15) :2129-2170.

Grgic I, Si H, Depboylu C, Höglinger GU, Busch C, Heyken WT, Kuhlmann U, Maier T, Kohler R, Hoyer J. Hyperkalaemia in a tetraplegic adolescent due to de novo sodium channel mutation. Nephrol Dial Transplant. 2008;23:1449-51.

Haag A, Knake S, Hamer HM et al. The Wada test in Austrian, Dutch, German, and Swiss epilepsy centers from 2000 to 2005: a review of 1421 procedures. Epilepsy Behavior 2008;13:83-89

Haag A, Knake S, Hamer HM, Boesebeck F, Freitag H, Schulz R, Baum P, Helmstaedter C, Wellmer J, Urbach H, Hopp P, Mayer T, Hufnagel A, Jokeit H, Lerche H, Uttner I, Meencke HJ, Meierkord H, Pauli E, Runge U, Saar J, Trinka E, Benke T, Vulliemoz S, Wiegand G, Stephani U, Wieser HG, Rating D, Werhahn K, Noachtar S, Schulze-Bonhage A, Wagner K, Alpherts WC, Boas WV, Rosenow F; for the Arbeitsgemeinschaft für prächirurgische Epilepsiediagnostik und operative Epilepsietherapie e.V. The Wada test in Austrian, Dutch, German, and Swiss epilepsy centers from 2000 to 2005: a review of 1421 procedures. Epilepsy Behav. 2008;13:83-89.

Happe S, Reese JP, Stiasny-Kolster K, Peglau I, Mayer G, Klotsch J, Giani G, Geraedts M, Trenkwalder C, Dodel R (2008) Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med 10(3):295-305.

Hattemer K, Knake S, Oertel WH, Hamer HM, Rosenow F. Recurrent v -induced seizures in a patient with chronic alcohol-abuse. Epileptic Disord 2008; 10: 162-164

Heller T, Nagel I; Ehrlich B, Bähr M, Strik HM. Automated CSF cytology with the Abbott CELL-DYN Sapphire™ system. Anal Quant Histol Cytol 2008, 30(3): 139-144

Herzog J, Pogarell O, Pinsker MO, Kupsch A, Oertel WH, Lindvall O, Deuschl G, Volkmann J. Deep brain stimulation in Parkinson’s disease following fetal nigra transplantation. Mov Disord 2008; 23: 1293-1296

Jauß M, Hamer HM. Doppler-und Duplexsonogaphie – neue Trends beim Schlaganfall. Neuroger 2008:5:91-94.

Jauß M, Hamer HM. Ultraschalldiagnostik zerebrovaskulärer Krankheiten in der Akutphase und Nachsorge. Klin Neurophysiol 2008 39:111-124.

Kallenberg K, Behrens A, Strik H, Knauth M. MR Imaging-Based Evidence of Vasogenic Brain Edema in a Case of Acute Acetone. Am J Neuroradiol. 2008, 29(4), e16 (Epub)

Kemlink D, Plazzi G, Vetrugno R, Provini F, Polo O, Stiasny-Kolster K, Oertel W, Nevsimalova S, Sonka K, Högl B, Frauscher B, Hadjigeorgiou GM, Pramstaller PP, Lichtner P, Meitinger T, Müller-Myshok B, Winkelmann J, Montagna P. Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics 2008; 9: 75-82

Klein KM, Preissig-Müller R, Knake S, Hamer HM, Oertel WH, Neubauer BA, Daut J, Rosenow F. Evaluation of susceptibility loci in an extended pedigree with idiopathic generalized epilepsy Epileptic Disorders 2008;10:13-8.

Klein KM, Theisen F, Knake S, Oertel WH, Hebebrand J, Rosenow F, Hamer HM. Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psychiatry. 2008 May;79(5):590-3.

Knake S, Gruener J, Hattemer K, Klein KM, Oertel WH, Hamer HM, Rosenow F. Intravenous Levetiracetam in the Treatment of Benzodiazepine-Refractory Status Epilepticus. J Neurol Neurosurg Psychiatry. 2008 May;79(5):588-9.

Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Ostergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK; on behalf of the European MSA Study Group (EMSA-SG). (2008) Red flags for multiple system atrophy. Mov Disord. 23(8):1093-9.

Leinweber B, Moller CJ, Scherag A, Reuner U, Günther P, Lang CJ, Schmidt HH, Schrader C, Bandmann O, Czlonkowska A, Oertel WH, Hefter H. Evaluation of the Unified Wilson’s Disease Rating Scale (UWDRS) in German patients with treated Wilson’s disease. Mov Disord 2008; 23: 54-62

Lünemann JD, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Münz C. Selective deregulation and myelin antigen recognition of EBNA1-specific T cells in Multiple Sclerosis, J Exp Med 2008; 205: 1763-1773.

Matusch A, Unger MM, Moeller C, Oertel WH. Other treatment related non-motor symptoms in Parkinson disease. In: Chaudhuri R (ed), Non motor symptoms in Parkinson disease. Oxford University Press

Mayer G, Kesper K, Ploch T, Canisius S, Penzel T, Oertel W, Stiasny-Kolster K. Quantification of tonic and phasic muscle activity in REM sleep behavior disorder. J Clin Neurophysiol 2008; 25: 48-55

Miller D, Knake S, Bauer S, Krakow K, Pagenstecher A, Sure U, Rosenow F. Intraoperative ultrasound to define focal cortical dysplasia in epilepsy surgery. Epilepsia. 2008;49:156-8

Moeller JC, Eggert KM, Unger M, Odin P, Chaudhuri R, Oertel WH. Clinical risk-benefit assessment of dopamine agonists. Eur J Neurol 2008; 15 Suppl 2: 15-23

Moeller JC, Oertel WH. A single question for the rapid screening of restless legs syndrome in the neurological clinical practice. Nat Clin Pract Neurol 2008; 4: 132-133

Moeller JC, Rissling I, Mylius V, Höft C; Eggert KM, Oertel WH. The prevalence of the G2019S and the R1441C/G/H mutations in LRRK2 in German patients with Parkinson’s disease. Eur J Neurol 2008; 15: 743-745

Moeller JC, Tackenberg B, Heinzel-Gutenbrunner M, Burmester R, Oertel WH, Bandmann O, Müller-Vahl KR. Immunophenotyping in Tourette syndrome – a pilot study. Eur J Neurol 2008; 15: 749-753

Möller JC, Eggert KM, Oertel WH. Sind alle Dopaminagonisten gleich ? INFO Neurol&Psychiat 2008; 10: 52-53

Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R (2008) Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev. 7(6):501-7.

Oertel W, Trenkwalder C. Vorwort. In : Restless Legs Syndrom. Informationsbuch und Ratgeber für behandelnde Ärzte und Betroffene. Deutsche Restless Legs Vereinigung e.V (Hrsg). 4. Auflage, RLS e.V., 2008, pp. 5-6

Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville KW, Schollmayer E, Kohnen R, Stiasny-Kolster K; On behalf of the Rotigotine SP709 Study Group. Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo controlled, six-week dose finding trial in Europe. Sleep Med 2008; 9: 228-239

Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Trenkwalder C, Tacken I, Schollmayer E, Kohnen R, Stiasny-Kolster K; Rotigotine SP710 Study Group. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008; 9(8): 865-873

Oertel WH, Poewe W, Wolters E, De Deyn PP, Emre M, Kirsch C, Hsu C, Tekin S, Lane R. Effects of rivastigmine on tremor and motor symptoms in patients with Parkinson’s disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Safety 2008; 31: 79-94

Oertel WH. Diagnostik der Demenz mit Lewy-Körperchen. INFO Neurol&Psychiat 2008; 10: 53

Oertel WH. Parkinson-Syndromes and other movement disorders. ERA-NET neuron workshop Report, Section 7, Paris 2008

Paulus W, Classen J, Cohen LG, Di Lazzaro V, Nitsche M, Pascual-Leone A, Rosenow F, Rothwell JC, Ziemann U. State of the art: Pharmacologic effects on cortical excitability measures as tested by transcranial magnetic stimulation. Brain Stimulation 2008:1:151-63

Popp J, Bacher M, Kölsch H, Noelker C, Deuster O, Dodel R, Jessen F (2008) Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res. 43(8): 749-53.

Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler; the ADVANS Study Group (… Oertel W). Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch Neurol 2008; 65: 577-583

Reif PS, Knake S, Iwinska-Zelder J, Hattemer K, Sure U, Hamer HM, Rosenow F. Epilepsie bei rechtshemisphärischer dualer Pathologie. Kavernom und Hamartom – Welche Läsion ist epileptogen? Z Epileptol 2008;21:30-35

Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008) Cognitive impairment in 873 patients with idiopathic Parkinson's disease: Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J. Neurol. 255(2):255-64.

Ries V, Oertel WH, Höglinger G. Neuroforum

Rosenow F, Hamer HM. Normales EEG der Erwachsenen inklusive der Normvarianten. Neurophysiol Lab 2008;29:189-198.

Schmidt D, Stefan H, Hamer HM, Elger CE. Frühe Kombinationstherapie bei Epilepsie mit modernen Antiepileptika: ein kritischer Überblick mit Empfehlungen. Nervenheilkunde 2008, 27:453-457.

Schmidt R, Neff F, Lampl C, Benke T, Anditsch M, Bancher C, Dal-Bianco P, Reisecker F, Marksteiner J, Rainer M, Kapeller P, Dodel R (2008) Therapie of Alzheimer’s Disease: Current status and future development. Neuropsychiatr. 22(3):153-71

Schneider F, Althaus A, Backes V, Dodel R (2008) Psychiatric Symptoms in Parkinson’s Disease. European Archives of Psychiatry and Clinical Neuroscience 258 Suppl 5:55-9.

Schormair B, Kemlink D, Roeske D, Eckstein G, Xiong L, Lichtner P, Ripke S, Trenkwalder C, Zimprich A, Stiasny-Kolster K, Oertel W, Bachmann CG, Paulus W, Högl B, Frauscher B, Geschliesser V, Poewe W, Peglau I, Vodicka P, Vavrova J, Sonka K, Nevsimalova S, Montplaisir J, Turecki G, Rouleau G, Gieger C, Illig T, Wichmann HE, Holsboer F, Müller-Myhsok B, Meitinger T, Winkelmann J. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature Genetics 2008; 40: 946-948

Shaw CA, Höglinger GU. Neurodegenerative Diseases: Are Neurotoxins Sufficient as the Sole Causal Factors? Neurmol Med. 2008;10:1-9.

Sommer N, Tackenberg B, Hohlfeld R. The immunopathogenesis of Myasthenia gravis. In: Engel A (ed.) Handbook of clinical Neurology; 2008, Vol. 91, Elsevier, London/New York, S. 169-212.

Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, Krisp A, Menke T, Schade-Brittinger C, Oertel WH, Höglinger GU. Short-term effects of coenzyme Q(10) in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 2008; 23: 942-949

Stiasny-Kolster K, Oertel W. Ursachen des Restless Legs Syndroms: Stand der Forschung. In : Restless Legs Syndrom. Informationsbuch und Ratgeber für behandelnde Ärzte und Betroffene. Deutsche Restless Legs Vereinigung e.V (Hrsg). 4. Auflage, RLS e.V., 2008, pp. 58-69

Strik H, Hoffmann A. Galectins in malignant gliomas: expression, functions and possible therapeutic options. In: “Galectins”, Klyosov A, Wijczak Z, Platt D (Ed.). Wiley Interscience, New Jersey 2008, 223-234. ISBN: 978-0-470-37318-7

Strik HM, Buhk JH, Wrede A, Hoffmann A, Bock C, Christmann M, Kaina B. Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Mol Med Rep 2008, 1(6): 863-9

Strzelczyk A, Bauer S, Knake S, Oertel WH, Hamer HM, Rosenow F.. Ictal asystole in temporal lobe epilepsy before and after pacemaker implantation. Epileptic Disorders 2008;10:39-44

Strzelczyk A, Moeller JC, Stamelou M, Matusch A, Oertel WH. Atypische Parkinson-Syndrome. CME. Nervenarzt 2008; 79: 1203-1222

Strzelczyk A, Nickolay T, Reese JP, Bauer S, Knake S, Rosenow F, Dodel R, Hamer HM (2008) Die direkten und indirekten Kosten therapierefraktärer Epilepsie. Neuro Rehabil 14(3) :133-140.

Strzelczyk A, Reese JP, Dodel R, Hamer HM (2008) Cost of Epilepsy : A systematic Review. PharmacoEconomics. 26(6) : 463-476

Strzelczyk A, Vogt H, Hamer HM, Krämer G. Continuous phenobarbital treatment leads to recurrent plantar fibromatosis: A case series and review of literature, Epilepsia 2008;49:1965-1968.

Tackenberg B, Gellert K, Kruth J, Oertel WH, Sommer N. „Myasthenia gravis –Diagnose, Therapie und besondere Probleme“. MMW Fortschr Med 2008; 150 (S2): 68-72.

Trenkwalder C, Benes H, Poewe W, Oertel WH, Garcia-Borreguero D, deWeerd AW, Ferini-Strambi L, Montagna P, Odin P, Stiasny-Kolster K, Högl B, Chaudhuri KR, Partinen M, Schollmayer E, Kohnen R; for the SP790 study group. Efficacy of rotigotine for treatment of moderate to severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2008; 7: 595-604

Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C. Treatment of Restless Legs Syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008; 23: 2267-2302

Unger M, Matusch A, Oertel WH. Non-motor symptoms in Parkinson’s disease. Treaching Course Syllabus. EFNS Madrid 24.08.2008

Unger M, Oertel WH. Non-dopamine lesions in PD – sleep disturbances Buchkapitel

Unger M, Reese JP, Oertel WH, Eggert K. Real-Life Evaluations of Compliance with Mandatory Drug Safety Monitoring Exemplified with Tolcapone in Parkinson’s Disease. Eur Neurol 2008; 60: 122-126

Unger MM, Moeller JC, Stiasny-Kolster K, Mankel K, Berg D, Walter U, Hoeffken H, Mayer G, Oertel WH. Assessment of idiopathic rapid-eye-movement sleep behaviour disorder by transcranial sonography, olfactory function test and FP-CIT-SPECT. Mov Disord 2008; 23: 596-599

Unger MM, Oertel WH, Thannickal TC, Lai Y-Y,Siegel JM. Non-dopaminergic lesions in Parkinson’s disease: Lesions associated with sleep disturbances.

Unger MM, Oertel WH. Case Study 9, Fluctuations in motor performance, wearing off. In: Schapira AHV, Hartmann A, Agid Y (eds), Parkinsonian Disorders in Clinical Practice. Wiley-Blackwell, Oxford 2008; pp. 103-106.

Wei X, Du Z, Zhao L, Feng D, Wei G, He Y, Tan J, Lee WH, Hampel H, Dodel R, Johnstone BH, March KL, Farlow MR, Du Y (2008) IFATS Series: The Conditioned Media of Adipose Stromal Cells Protect Against Hypoxia-Ischemia-Induced Brain Damage in Neonatal Rats. Stem Cells 27(2):478-488.

Wei X, Ma Z, Fontanilla CV, Zhao L, Xu ZC, Taggliabraci V, Johnstone BH, Dodel RC, Farlow MR, Du Y (2008) Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity. Neuroscience 155(4):1098-105

Wentrup A, Oertel WH, Dodel R (2008) Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease. Drug Design, Development and Therapie 2 245–254.

Winter Y, Dodel R, Haacke C, Schaeg M, Schöffski O, Oertel W, Bach T (2008) Kostenstruktur der Schlaganfallsbehandlung in Deutschl. Neuro & Rehabil 14(2) :59-65.

Winter Y, Wolfram C, Schöffski O, Dodel RC, Back T (2008) Long-term disease-related costs 4 years after stroke or TIA in Germany. Nervenarzt 79(8) :918-26.